<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="158083">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01914393</url>
  </required_header>
  <id_info>
    <org_study_id>D1050302</org_study_id>
    <secondary_id>2013-001694-24</secondary_id>
    <nct_id>NCT01914393</nct_id>
  </id_info>
  <brief_title>Pediatric Open-Label Extension Study</brief_title>
  <official_title>A 104-Week, Flexible-Dose, Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Effectiveness of Lurasidone in Pediatric Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunovion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunovion</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Ukraine: Ministry of Health</authority>
    <authority>Italy: The Italian Medicines Agency</authority>
    <authority>Serbia: Medicines and Medical Devices Agency</authority>
    <authority>Bulgaria: Bulgarian Drug Agency</authority>
    <authority>Colombia: National Institutes of Health</authority>
    <authority>China: Ministry of Health</authority>
    <authority>Romania: National Medicines Agency</authority>
    <authority>Spain: Spanish Agency of Medicines</authority>
    <authority>Korea: Food and Drug Administration</authority>
    <authority>Malaysia: Ministry of Health</authority>
    <authority>Philippines : Food and Drug Administration</authority>
    <authority>Mexico: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, 104-week, multicenter, extension study designed to evaluate the
      long-term safety, tolerability and effectiveness of flexibly dosed lurasidone (20, 40, 60 or
      80 mg/day) in pediatric subjects who have completed the 6-week treatment period in the
      preceding studies, D1050301, D1050325, and D1050326
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of treatment-emergent adverse events (TEAEs), TEAEs leading to discontinuation and serious AEs (SAEs)</measure>
    <time_frame>104 Weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Laboratory tests</measure>
    <time_frame>104 Weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Movement disorders as assessed by Abnormal Involuntary Movement Scale (AIMS), Barnes Akathisia Rating Scale (BARS), and the Simpson-Angus Scale (SAS)</measure>
    <time_frame>104 Weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Tanner staging, and menstrual cyclicity (female subjects)</measure>
    <time_frame>104 Weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Vital Signs</measure>
    <time_frame>104 Weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Vital signs following 5 minutes of seated rest will consist of supine systolic and diastolic blood pressures, respiration rate, heart rate, and oral body temperature.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Body weight and body mass index</measure>
    <time_frame>104 Weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Physical Examination</measure>
    <time_frame>104 Weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The physical examination includes an assessment of general appearance and a review of systems (dermatologic, head, eyes, ears, nose, mouth/throat/neck, thyroid, lymph nodes, respiratory, cardiovascular, gastrointestinal, extremities, musculoskeletal, neurologic, and psychiatric systems).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in height (as measured by stadiometer)</measure>
    <time_frame>104 Weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in electrocardiogram</measure>
    <time_frame>104 Weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>All ECGs will be obtained in the supine position, after the subject has been resting supine for at least 10 minutes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Columbia Suicide Severity Rating Scale (C-SSRS)</measure>
    <time_frame>104 Weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CogState Computerized Cognitive Test Battery</measure>
    <time_frame>104 Weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Udvalg for Kliniske Undersogelser Side Effect Rating Scale (UKU)</measure>
    <time_frame>104 Weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression-Severity (CGI-S) scale</measure>
    <time_frame>104 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive and Negative Syndrome Scale (PANSS)</measure>
    <time_frame>104 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinician-rated Children's Global Assessment Scale (CGAS)</measure>
    <time_frame>104 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q)</measure>
    <time_frame>104 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aberrant Behavior Checklist (ABC)</measure>
    <time_frame>104 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Children's Yale-Brown Obsessive Compulsive Scales</measure>
    <time_frame>104 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caregiver Strain Questionnaire (CGSQ)</measure>
    <time_frame>104 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Children's Depression Rating Scale, Revised (CDRS-R)</measure>
    <time_frame>104 Weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Young Mania Rating Scale (YMRS)</measure>
    <time_frame>104 Weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression-Bipolar Version, Severity of Illness (CGI-BP-S)</measure>
    <time_frame>104 Weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pediatric Anxiety Rating Scale (PARS)</measure>
    <time_frame>104 Weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Attention Deficit/Hyperactivity Disorder Rating Scale (ADHD-RS)</measure>
    <time_frame>104 Weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">295</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Autism</condition>
  <condition>Bipolar Depression</condition>
  <arm_group>
    <arm_group_label>Lurasidone 20, 40, 60, 80 mg, flexibly dosed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lurasidone 20, 40, 60, 80 mg, flexibly dosed, once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lurasidone 20, 40, 60, 80 mg, flexibly dosed</intervention_name>
    <description>Lurasidone 20, 40, 60, 80 mg once daily, flexibly dosed</description>
    <arm_group_label>Lurasidone 20, 40, 60, 80 mg, flexibly dosed</arm_group_label>
    <other_name>Latuda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent from parent(s) or legal guardian(s) with sufficient
             intellectual capacity to understand the study and support subjects' participation in
             the study procedures must be obtained for subjects who are not emancipated. In
             accordance with Institutional Review Board (IRB) or Independent Ethics Committee
             (IEC) requirements, the subject will complete an informed assent when developmentally
             appropriate, to participate in the study before conduct of any study-specific
             procedures.

          -  Subject has completed Study D1050301 (Visit 9) OR

          -  Subject has completed Study D1050325 (Visit 9) OR

          -  Subject has completed Study D1050326 (Visit 8)

          -  Subject is judged by the investigator to be appropriate for participation in a
             104-week clinical trial in an outpatient setting involving open-label lurasidone
             treatment, and is able to comply with the protocol.

          -  A reliable informant (eg, parent, legal guardian, or caregiver) must be available to
             accompany the subject at each visit.  For subjects entering from Study D1050325, the
             reliable caregiver must also oversee the administration of the study drug throughout
             the study

          -  Females who participate in this study:

               -  are unable to become pregnant (eg, premenarchal, surgically sterile, etc.) -OR-

               -  practices true abstinence (consistent with lifestyle) and must agree to remain
                  abstinent from signing informed consent to at least 7 days after the last dose
                  of study drug has been taken; -OR-

               -  are sexually active and willing to use a medically effective method of birth
                  control (eg, male using condom and female using condom, diaphragm, contraceptive
                  sponge, spermicide, contraceptive pill, or intrauterine device) from signing
                  informed consent to at least 7 days after the last dose of study drug has been
                  taken.

          -  Males must be willing to remain sexually abstinent (consistent with lifestyle) or use
             an effective method of birth control (eg, male using condom and female using condom,
             diaphragm, contraceptive sponge, spermicide, contraceptive pill, or intrauterine
             device) from signing informed consent to at least 7 days after the last dose of study
             drug has been taken.

        Exclusion Criteria:

          -  Subject is considered by the investigator to be at imminent risk of suicide.

          -  Exhibits evidence of moderate or severe extrapyramidal symptoms, dystonia, tardive
             dyskinesia, or any other moderate or severe movement disorder. Severity to be
             determined by the investigator.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lurasidone Medical Director, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sunovion</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Medical Director</last_name>
    <phone>1-866-503-6351</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Harmonex Neuroscience Research</name>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <zip>36303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nelson Handel, MD</last_name>
      <phone>334-836-2000</phone>
      <email>nhandal@harmonex.us</email>
    </contact>
    <investigator>
      <last_name>Nelson Handel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarkis Clinical Trials - Parent</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elias Sarkis, MD</last_name>
      <phone>352-333-0094</phone>
      <email>ok@ehsfamily.com</email>
    </contact>
    <investigator>
      <last_name>Elias Sarkis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Palm Springs Research Institute</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel Perez, MD</last_name>
      <phone>305-298-3179</phone>
      <email>mnadal2003@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Miguel Perez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc.</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nandita Joshi, MD</last_name>
      <phone>904-281-5757</phone>
      <email>njoshi@cnshealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Nandita Joshi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Research Group of Central Florida</name>
      <address>
        <city>Sanford</city>
        <state>Florida</state>
        <zip>32771</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adly Thebaud, MD</last_name>
      <phone>386-775-7627</phone>
      <email>athebaud@mrgcf.com</email>
    </contact>
    <investigator>
      <last_name>Adly Thebaud, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atlanta Center for Medical Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andro Giorgadze, MD</last_name>
      <phone>404-881-5800</phone>
      <email>agiorgadze@acmr.org</email>
    </contact>
    <investigator>
      <last_name>Andro Giorgadze, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Attalla Consultants, LLC</name>
      <address>
        <city>Smyrna</city>
        <state>Georgia</state>
        <zip>30080</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashraf Attalla, MD</last_name>
      <phone>770-319-8025</phone>
      <email>pi@drashrafattalla.com</email>
    </contact>
    <investigator>
      <last_name>Ashraf Attalla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Capstone Clinical Research, Inc.</name>
      <address>
        <city>Libertyville</city>
        <state>Illinois</state>
        <zip>60048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Greenbaum, MD</last_name>
      <phone>847-549-7214</phone>
      <email>mgreenbaum@capstoneclinical.com</email>
    </contact>
    <investigator>
      <last_name>Michael Greenbaum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baber Research Group</name>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <zip>60563</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Riaz Baber, MD</last_name>
      <phone>630-844-2095</phone>
      <email>freeda@baberresearchgroup.com</email>
    </contact>
    <investigator>
      <last_name>Riaz Baber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lake Charles Clinical Trials LLC,2770 3rd Avenue,Suite 340</name>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <zip>70601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kasinath G Yadalam, MD</last_name>
      <phone>337-494-3266</phone>
      <email>yadalam@aol.com</email>
    </contact>
    <investigator>
      <last_name>Kasinath G Yadalam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Psychiatry and Behavioral Medicine, Inc.</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann Childress, MD</last_name>
      <phone>702-838-0742</phone>
      <email>drann87@aol.com</email>
    </contact>
    <investigator>
      <last_name>Ann Childress, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Childrens Specialized Hospital</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08755</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yvette Janvier, MD</last_name>
      <phone>732-914-1100</phone>
      <email>yjanvier@childrens-specialized.org</email>
    </contact>
    <investigator>
      <last_name>Yvette Janvier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Finger Lakes Clinical Research</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>10618</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Atkinson, MD</last_name>
      <phone>585-241-9670</phone>
      <email>sda@flclinical.com</email>
    </contact>
    <investigator>
      <last_name>Sarah Atkinson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Richmond Behavioral Associates</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10312</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark DiBuono, MD</last_name>
      <phone>718-317-5522</phone>
      <email>dibuono@rbany.com</email>
    </contact>
    <investigator>
      <last_name>Mark DiBuono, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa DelBello, MD</last_name>
      <phone>513-245-3415</phone>
      <email>delbelmp@email.uc.edu</email>
    </contact>
    <investigator>
      <last_name>Melissa DelBello, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cutting Edge Research Group</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73116</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Willis Holloway, MD</last_name>
      <phone>405-603-8068</phone>
      <email>wholloway@cuttingedgeresearch.org</email>
    </contact>
    <investigator>
      <last_name>Willis Holloway, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cyn3rgy Research &amp; Development</name>
      <address>
        <city>Gresham</city>
        <state>Oregon</state>
        <zip>97030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Calcagno, MD</last_name>
      <phone>503-907-2179</phone>
      <email>jcalcagno@cyn3rgy.com</email>
    </contact>
    <investigator>
      <last_name>John Calgano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Segal Institute for Clinical Research</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Lopez, MD</last_name>
      <phone>843-576-6750</phone>
      <email>bsegal@segalinstitute.com</email>
    </contact>
    <investigator>
      <last_name>Steven Lopez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Strategies of Memphis, LLC</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anita Varma, MD</last_name>
      <phone>901-685-8890</phone>
      <email>varmamd@researchmemphis.com</email>
    </contact>
    <investigator>
      <last_name>Anita Varma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BioBehavioral Research of Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Divyansu Patel, MD</last_name>
      <phone>512-382-6661</phone>
      <email>patel@bbraustin.com</email>
    </contact>
    <investigator>
      <last_name>Divyansu Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pillar Clinical Research, LLC</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75243</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Bartley, MD</last_name>
      <phone>214-388-6455</phone>
      <email>sbartley@pillarhc.com</email>
    </contact>
    <investigator>
      <last_name>Scott Bartley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Family Psychiatry of The Woodlands, P.A.</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77381</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marshall Lucas, MD</last_name>
      <phone>281-367-1015</phone>
      <email>mlucasmd2011@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Marshall Lucas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ericksen Research &amp; Development, LLC</name>
      <address>
        <city>Clinton</city>
        <state>Utah</state>
        <zip>84015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha Bostrom, MD</last_name>
      <phone>801-614-5501</phone>
      <email>amy-kim@westsidemedical.org</email>
    </contact>
    <investigator>
      <last_name>Samantha Bostrom, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CRI Lifetree</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reid Robison, MD</last_name>
      <phone>801-269-8200</phone>
      <email>rrobison@crilifetree.com</email>
    </contact>
    <investigator>
      <last_name>Reid Robison, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neuroscience, Inc.</name>
      <address>
        <city>Herndon</city>
        <state>Virginia</state>
        <zip>20170</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keith Saylor, MD</last_name>
      <phone>703-787-9090</phone>
      <email>ksaylor@neuroscience-inc.com</email>
    </contact>
    <investigator>
      <last_name>Keith Saylor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pacific Institute Of Medical Sciences</name>
      <address>
        <city>Bothell</city>
        <state>Washington</state>
        <zip>98011</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Syed Mustafa, MD</last_name>
      <phone>425-949-5779</phone>
      <email>souad@pspc.org</email>
    </contact>
    <investigator>
      <last_name>Syed Mustafa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 14, 2014</lastchanged_date>
  <firstreceived_date>July 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <keyword>Autism</keyword>
  <keyword>Lurasidone</keyword>
  <keyword>Latuda</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
